COMMITMENTS AND CONTINGENCIES (Detail) (USD $)	0 Months Ended	12 Months Ended		0 Months Ended	12 Months Ended										0 Months Ended	12 Months Ended		0 Months Ended	12 Months Ended
	Aug. 31, 2016	May 31, 2012	May 31, 2011	Aug. 31, 2016 Opearating Lease Rental	May 31, 2012 Mexico	May 31, 2011 Mexico	May 31, 2012 Minimum [Member] Enzyme Linked Immunosorbent	May 31, 2012 Minimum [Member] Thiopurine Drugs	May 31, 2012 Maximum [Member] Enzyme Linked Immunosorbent	May 31, 2011 Maximum [Member] Thiopurine Drugs	May 31, 2012 Medical Diagnostic Test	May 31, 2011 Medical Diagnostic Test	May 31, 2012 Enzyme Linked Immunosorbent	May 31, 2011 Enzyme Linked Immunosorbent	Jun. 30, 2010 Thiopurine Drugs	May 31, 2012 Thiopurine Drugs	May 31, 2011 Thiopurine Drugs	Oct. 19, 2010 Patents Owned By University	May 31, 2012 Patents Owned By University	May 31, 2011 Patents Owned By University	May 31, 2012 Royalty Agreement For The Life Of The Products	May 31, 2011 Royalty Agreement For The Life Of The Products
Operating Leases, Agreement Date		Jun. 18, 2009
Operating Leases, Commencement Date		Sep. 01, 2009
Lease Expiration Date		Aug. 31, 2016
Operating Leases, Rent Expense, Minimum Rentals				$ 18,490
Operating Leases, Rent Expense, Contingent Rentals	22,080
Security Deposit Liability	22,080
Operating Leases, Rent Expense		235,984	231,903		36,302	35,584
Operating Leases, Rent Expense, Net		202,984	228,903
Operating Leases, Income Statement, Sublease Revenue		33,000	3,000
Royalty Expense, Percentage of Sales							4.00%	4.00%	8.00%	8.00%	10.00%										3.40%
Royalty Expense											5,500	6,000	16,500	3,750		10,294	0		8,000	4,000	30,000	57,000
License Costs													25,000					15,000
License Cost Amortization Period													10 years
Payments for Patents															25,000
Finite-Lived Intangible Assets, Accumulated Amortization		$ 50,591	$ 17,764													$ 5,000			$ 12,300
Royalty Expenses Percentage																						7.20%